论文部分内容阅读
目的:分析新型雌激素受体ERα36在子宫内膜癌组织中的表达与临床病理特征的关系。方法:免疫组织化学方法检测73例子宫内膜癌、20例正常子宫内膜、9例不典型增生子宫内膜组织切片ERα36的表达,并分析其与临床病理特征间的关系。结果:ERα36在子宫内膜癌组织中阳性表达率(32.9%,24/73)显著低于正常子宫内膜组织(85%,17/20)(P<0.01);ERα36阴性表达者较阳性表达者出现更多宫颈受侵(48.9%vs 20.8%,P<0.05);ERα36阳性表达者无疾病生存时间短于阴性表达者(P<0.01);ERα36表达与患者年龄、临床分期、组织学分级、肌层浸润、淋巴结转移和病理类型的差异无统计学意义(P>0.05);ERα36表达与ER、PR、PTEN、p53无显著相关性(P>0.05)。结论:ERα36在子宫内膜癌组织的表达明显低于正常子宫内膜组织;ERα36表达与ER无明显相关性,可能是子宫内膜癌预后的一个指标。
Objective: To analyze the relationship between the expression of novel estrogen receptor ERα36 and clinicopathological features in endometrial carcinoma. Methods: Immunohistochemistry was used to detect the expression of ERα36 in 73 cases of endometrial carcinoma, 20 cases of normal endometrium and 9 cases of atypical hyperplasia. The relationship between the expression of ERα36 and clinicopathological features was analyzed. Results: The positive rate of ERα36 in endometrial carcinoma (32.9%, 24/73) was significantly lower than that in normal endometrium (85%, 17/20) (P <0.01). The positive expression of ERα36 in ERα36 (48.9% vs 20.8%, P <0.05). The disease-free survival of ERα36 positive patients was shorter than that of negative ones (P <0.01). The expression of ERα36 was correlated with age, clinical stage, histological grade (P> 0.05). There was no significant correlation between ERα36 expression and ER, PR, PTEN and p53 (P> 0.05). Conclusion: The expression of ERα36 in endometrial carcinoma was significantly lower than that in normal endometrial tissue. The expression of ERα36 was not correlated with ER, which may be an indicator of the prognosis of endometrial carcinoma.